252 related articles for article (PubMed ID: 27183221)
21. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.
Mitchell AP; Winn AN; Lund JL; Dusetzina SB
Oncologist; 2019 May; 24(5):632-639. PubMed ID: 30728276
[TBL] [Abstract][Full Text] [Related]
22. Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States.
Murayama A
Int J Rheum Dis; 2024 Jan; 27(1):e14962. PubMed ID: 37923570
[TBL] [Abstract][Full Text] [Related]
23. Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination.
Marcum ZA; Chang CY; Barthold D; Holmes HM; Lo-Ciganic WH
Neurol Clin Pract; 2021 Jun; 11(3):181-187. PubMed ID: 34484885
[TBL] [Abstract][Full Text] [Related]
24. Association between physician characteristics and payments from industry in 2015-2017: observational study.
Inoue K; Blumenthal DM; Elashoff D; Tsugawa Y
BMJ Open; 2019 Sep; 9(9):e031010. PubMed ID: 31542759
[TBL] [Abstract][Full Text] [Related]
25. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
[TBL] [Abstract][Full Text] [Related]
26. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2018 Sep; 159(3):442-448. PubMed ID: 29865931
[TBL] [Abstract][Full Text] [Related]
27. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
28. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data.
Feng H; Wu P; Leger M
JAMA Dermatol; 2016 Dec; 152(12):1307-1313. PubMed ID: 27706478
[TBL] [Abstract][Full Text] [Related]
29. Types and Distribution of Payments From Industry to Physicians in 2015.
Tringale KR; Marshall D; Mackey TK; Connor M; Murphy JD; Hattangadi-Gluth JA
JAMA; 2017 May; 317(17):1774-1784. PubMed ID: 28464140
[TBL] [Abstract][Full Text] [Related]
30. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
Mehta HB; Moore TJ; Alexander GC
Psychiatr Serv; 2021 Jan; 72(1):77-80. PubMed ID: 32838675
[TBL] [Abstract][Full Text] [Related]
31. Orthopaedics and the Physician Payments Sunshine Act: An Examination of Payments to U.S. Orthopaedic Surgeons in the Open Payments Database.
Iyer S; Derman P; Sandhu HS
J Bone Joint Surg Am; 2016 Mar; 98(5):e18. PubMed ID: 26935466
[TBL] [Abstract][Full Text] [Related]
32. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study.
Goel V; Moran B; Kaizer AM; Sivanesan E; Patwardhan AM; Ibrahim M; DeWeerth JC; Shannon C; Shankar H
Anesth Analg; 2021 Jun; 132(6):1748-1755. PubMed ID: 33591120
[TBL] [Abstract][Full Text] [Related]
33. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
Modi PK; Wang Y; Kirk PS; Dupree JM; Singer EA; Chang SL
Urology; 2018 Jul; 117():50-56. PubMed ID: 29680480
[TBL] [Abstract][Full Text] [Related]
34. The Sunshine Act and Surgeons: A Nation-Wide Analysis of Industry Payments to Physicians.
Garstka ME; Monlezun D; DuCoin C; Killackey M; Kandil E
J Surg Res; 2019 Jan; 233():41-49. PubMed ID: 30502279
[TBL] [Abstract][Full Text] [Related]
35. The Physician Payments Sunshine Act: data evaluation regarding payments to ophthalmologists.
Chang JS
Ophthalmology; 2015 Apr; 122(4):656-61. PubMed ID: 25578254
[TBL] [Abstract][Full Text] [Related]
36. Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.
Yanagisawa M; Blumenthal DM; Kato H; Inoue K; Tsugawa Y
J Gen Intern Med; 2022 May; 37(7):1626-1633. PubMed ID: 34378113
[TBL] [Abstract][Full Text] [Related]
37. Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program.
Marshall DC; Jackson ME; Hattangadi-Gluth JA
Mayo Clin Proc; 2016 Jan; 91(1):84-96. PubMed ID: 26763512
[TBL] [Abstract][Full Text] [Related]
38. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
39. Industry Financial Relationships in Neurosurgery in 2015: Analysis of the Sunshine Act Open Payments Database.
de Lotbiniere-Bassett MP; McDonald PJ
World Neurosurg; 2018 Jun; 114():e920-e925. PubMed ID: 29581013
[TBL] [Abstract][Full Text] [Related]
40. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.
Lai LY; Oerline MK; Kaufman SR; Herrel LA; Skolarus TA; Dusetzina SB; Ellimoottil C; Shahinian VB; Hollenbeck BK; Caram MEV
Urology; 2022 Mar; 161():50-58. PubMed ID: 34861316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
